Simulations Plus, a provider of simulation and modeling software for pharmaceutical industry, has signed a collaboration agreement with a top-5 pharmaceutical company to extend and enhance its oral cavity dosing model within its industry gold standard GastroPlus simulation software program.
The collaboration is expected to exhance the GastroPlus simulation model for drug dosing in the oral cavity, such as sublingual, lingual and bucca dosing through a variety of dosage forms.
Simulations Plus chairman and chief executive officer Walt Woltosz said these agreements will continue to extend the competitive advantage of our GastroPlus program, adding industry leading capabilities without the need for Simulations Plus to fund the development directly.
“When it is appropriate for a particular drug, oral cavity dosing can have significant advantages over traditional swallowed oral doses, including more rapid absorption and onset of action, and reduced loss of drug due to first-pass metabolism in the liver,” Woltosz said.
Simulations Plus vice president of marketing and sales John DiBella said this is the compay’s first new funded collaboration since it completed several others two years ago.
“The funding support we will receive will add to our steady growth in software licensing revenues, which has had to make up for the lack of collaboration funding in recent quarters when compared to their year-previous quarters, as well as adding to the revenue growth we’ve experienced,” DiBella said.
The company is currently in negotiations with another top pharmaceutical company for another funded collaboration intended to enhance GastroPlus.
